Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04053283 · ClinicalTrials.gov registry record · Phase 1
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
A Phase 1 study, sponsored by Akamis Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 186
- Enrollment target
NCT04053283: Completed Phase 1 study, sponsored by Akamis Bio.
NCT04053283 is a Phase 1 study that has completed, run by Akamis Bio. The registered enrollment target is 186 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (210% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04053283, a Phase 1 study, has completed, sponsored by Akamis Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 186 participants
- Enrollment target
Study Summary
To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.
Primary Outcome
Incidence of adverse events, adverse events meeting protocol-defined DLT criteria, adverse events leading to study treatment or study discontinuation, and adverse events resulting in death.
Interventions
- BIOLOGICAL NG-641
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2023-12-20 |
| Phase | Phase 1 |
What the finished NCT04053283 record still lists
NCT04053283 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (210% higher).
The record links to 0 conditions, and to 1 intervention - of which NG-641 is the first listed.
NCT04053283 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04053283 about?
NCT04053283 is a clinical study titled "First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector". To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.
What is the current status of trial NCT04053283?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 186 participants. The study started on 2020-01-23. Estimated completion is 2023-12-20.
What interventions are being tested in trial NCT04053283?
The interventions under investigation include: NG-641 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04053283?
This trial is sponsored by Akamis Bio, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04053283's enrollment target sits among peer trials
186 291st of 2000 higher than 1,707 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI